Qianhai Health Holdings Ltd. (0911) AI Stock Analysis

Qianhai Health Holdings Ltd.

(HKEX:0911)

Select Model

Rating:57Neutral

Price Target:HKD 0.33▲(3.49% Upside)

Action:reiterated

Date:09/15/26

The overall score reflects a company in an early but fragile turnaround: balance sheet strength and improving cash flows support a moderate rating, while thin margins, volatile revenue, and a clear downward price trend with oversold technicals temper the outlook. Valuation appears reasonable for the risk profile but does not strongly offset the operational and market‑trend uncertainties.

Positive Factors

Return to profitabilityThe return to positive net income and operating profit marks a meaningful improvement from the prior loss-making period. If maintained, profitability can support internal funding, strengthen financial resilience, and provide a more stable base for future operations over the next several quarters.

Negative Factors

Very thin marginsMargins at these levels leave limited protection against pricing pressure or cost increases, so relatively small changes in operating performance could materially affect earnings. The decline from 2024 also suggests that the return to profitability remains fragile rather than yet representing a durable high-quality margin structure.

Qianhai Health Holdings Ltd. (0911) vs. iShares MSCI Hong Kong ETF (EWH)

Market Cap: HKD 51.68M
Dividend Yield: ―
Average Volume (3M): 64.75K
Price to Earnings (P/E): 13.3
Beta (1Y): 0.06
Revenue Growth: -18.16%
EPS Growth: ―
Country: Hong Kong
Employees: 19
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Qianhai Health Holdings Ltd. Business Overview & Revenue Model

Company Description

Qianhai Health Holdings Limited (0911.HK) functions as an investment holding company primarily focused on the distribution of health products and electronic components within Hong Kong. Its operations are structured into two main divisions: Health-Ca...

Qianhai Health Holdings Ltd. Financial Statement Overview

Summary

Financial performance has turned from sizeable losses to modest profits with improving cash generation and very low leverage, but profitability remains thin, revenue highly volatile, and long‑term returns on equity weak, placing overall strength in the mid range.

Income Statement

52Neutral

Balance Sheet

68Positive

Cash Flow

63Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	453.03M	677.12M	519.70M	961.29M	1.96B	283.40M
Gross Profit	15.82M	22.26M	29.67M	-35.60M	76.48M	16.04M
EBITDA	5.29M	7.19M	16.32M	-50.23M	-231.24M	2.06M
Net Income	4.01M	5.94M	1.31M	-52.70M	-233.70M	-888.00K
Balance Sheet
Total Assets	441.43M	408.39M	407.31M	478.12M	534.43M	738.63M
Cash, Cash Equivalents and Short-Term Investments	17.88M	61.38M	23.51M	19.52M	1.64M	2.47M
Total Debt	107.00K	424.00K	1.03M	487.00K	1.19M	7.83M
Total Liabilities	47.39M	17.19M	21.74M	94.00M	97.73M	68.09M
Stockholders Equity	394.05M	391.20M	385.57M	384.11M	436.70M	670.53M
Cash Flow
Free Cash Flow	-8.64M	38.78M	4.19M	857.00K	-5.26M	-44.19M
Operating Cash Flow	-8.64M	38.80M	4.20M	857.00K	-5.26M	-44.18M
Investing Cash Flow	-3,000	-14.00K	246.00K	17.77M	12.34M	46.84M
Financing Cash Flow	-648.00K	-648.00K	-712.00K	-743.00K	-7.91M	-16.56M

Qianhai Health Holdings Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price0.32

Price Trends

50DMA0.40Negative

100DMA0.52Negative

200DMA0.48Negative

Market Momentum

MACD-0.03Negative

RSI28.04Positive

STOCH5.17Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0911, the sentiment is Negative. The current price of 0.32 is below the 20-day moving average (MA) of 0.34, below the 50-day MA of 0.40, and below the 200-day MA of 0.48, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 28.04 is Positive, neither overbought nor oversold. The STOCH value of 5.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0911.

Qianhai Health Holdings Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

HK:0911 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:2633	70Outperform	HKD 1.78B	6.16	13.26%	9.73%	-0.47%	-0.40%
HK:0897	59Neutral	HKD 401.18M	100.00	0.34%	―	-8.30%	-44.44%
HK:0911	57Neutral	HKD 53.38M	13.29	1.02%	―	-18.16%	―
HK:0858	54Neutral	HKD 147.90M	-0.11	-154.56%	―	-7.12%	-523.61%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:0455	44Neutral	HKD 191.35M	-2.73	-14.55%	―	12.89%	-2.56%
HK:1498	42Neutral	HKD 123.04M	-4.04	-21.66%	―	-6.71%	43.14%

* Healthcare Sector Average

Performance Comparison

HK:0911 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
HK:0911	Qianhai Health Holdings Ltd.	0.32	-0.03	-7.35%
HK:0858	Extrawell Pharmaceutical Holdings Limited	0.04	-0.05	-52.22%
HK:0455	Tianda Pharmaceuticals Ltd.	0.09	-0.04	-29.92%
HK:0897	Wai Yuen Tong Medicine Holdings Limited	0.36	-0.09	-20.00%
HK:1498	PuraPharm Corp. Ltd.	0.23	-0.17	-42.50%
HK:2633	Jacobson Pharma Corporation Limited	0.93	-0.41	-30.60%

Qianhai Health Holdings Ltd. Corporate Events

Qianhai Health Shifts Hong Kong Principal Office to Causeway Bay

Sep 18, 2026

Qianhai Health Holdings Limited has announced a change to its principal place of business in Hong Kong, which will move to Room 1622, 16/F, Leighton Centre, 77 Leighton Road, Causeway Bay, effective 22 September 2026. The company emphasized that its...

Qianhai Health’s Interim Profit Holds Up Despite Sharp Revenue Drop

Aug 12, 2026

Qianhai Health Holdings reported unaudited interim revenue of HK$116.76 million for the six months ended 30 June 2026, down sharply from HK$340.85 million a year earlier, with gross profit falling to HK$7.71 million from HK$14.16 million as cost of s...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 22, 2026

Qianhai Health Holdings Ltd. AI Stock Analysis